Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Listen to the most recent Podcasts developed by ESMO Open.

HRD testing for advanced high-grade ovarian carcinoma in first line

In this podcast Dr Silvia Puglisi, of the IRCCS Ospedale Policlinico San Martino, Genoa, discusses HRD testing for advanced high grade ovarian carcinoma in first line with Prof. Ian McNeish, of Imperial College London, and Dr Antonio Gonzáles Martin, of the Clinica Universidad de Navarra, Madrid. 
International guidelines strongly recommend the use of the homologous recombination deficiency (HRD) test in the selection of first-line maintenance therapy for patients with high-grade serous ovarian cancer. The test has significant prognostic and, importantly, predictive value for the response to PARP inhibitors. However, in some situations the test is not available.

Published in June 2024

ADCs in HER2+ metastatic breast cancer brain metastases

ESMO Open Editor-in-Chief Giuseppe Curgliano introduces a discussion between Dr Sara Hurwitz, of the Fred Hutcinson Cancer Center, Seattle, USA, and Dr Nancy Lin, of the Dana-Farber Cancer Institute, Boston USA, with ESMO Open Associate Editor Dr Paolo Tarantino, on the occasion of the publication of their articles on antibody-drug conjugate activity in patients with HER2-positive breast cancer brain metastases.

Published on 24 Apr 2024

Molecular testing in endometrial cancer

In this podcast Dr Ainhoa Madariaga, of the Gynecology and Breast Cancer Unit, 12 de Octubre University Hospital, Madrid, Spain, discusses the requirements for molecular testing to be done in endometrial cancer with Dr Tjalling Bosse, of the Department of Pathology, Leiden University Medical Center, The Netherlands.

Published on 11 Apr 2024

Immune-checkpoint inhibitors alone or in combination for the endometrial MMRd/MSI-H population

Molecular classification of endometrial cancer has changed the understanding of the distinct pathways underlying this heterogeneous cancer and paved the way to new therapeutic approaches. Mismatch repair deficient/microsatellite high (MMRd/MSI-H) tumours comprise up to 30% of cases. In this podcast Professors Nicoletta Colombo, of the Istituto Europeo di Oncologia IRCCS, Milan, Italy, and Florence Joly, of the Centre François-Baclesse, University of Caen Normandy, France, discuss existing and emerging treatment strategies incorporating immune checkpoint inhibitors with Dr Rita Canario, of Portuguese Oncology Institute of Porto, Porto, Portugal.

Published on 5 Mar 2024

First-line maintenance treatment of high grade serous ovarian cancer with a BRCA1/2 mutation

The best first-line maintenance treatment in a high grade serous ovarian cancer patient carrying a BRCA1/2 mutation is still up for debate. In this podcast Dr Margherita Turinetto, of the University of Turin, Italy, discusses the issues and data with Professor Isabelle Ray-Coquard, of the Centre Leon Berard, France, and Professor Charlie Gourley, Clinical Director, Cancer Research UK Scotland Centre, UK.

Published on 16 Feb 2024

A place for hormonal therapy in endometrial carcinoma?

Endometrial cancer is the most common gynaecological malignancy in developed nations, exhibiting rising incidence and mortality rates worldwide. In this podcast Dr Irene Giannubilo, of the Ospedale Policlinico San Martino, Genoa, Italy, discusses the possibilities for endocrine therapy for women with endometrial cancer with Professor Mansoor Raza Mirza, Copenhagen University Hospital, Denmark, and Professor Frederik Marmé, the University of Heidelberg Women's Hospital, Germany.

Published on 14 Feb 2024

Focus on systemic therapy for ovarian clear cell carcinoma

In this podcast, Dr Maria Kfoury, of Institut Paoli-Calmettes (IPC), Marseille, France, and Professor David Tan, of the National University Cancer Institute, Singapore, discuss developments in research in the systemic therapy of ovarian clear cell carcinoma: Are there any specific issues, and should they be treated separately?

Published on 31 Jan 2024

Surgery and HIPEC in relapse for all patients with Ovarian Cancer

Dr Shira Peleg Hasson, from The Royal Marsden NHS Foundation Trust, London, UK, leads a debate between Dr Philipp Harther (Kliniken Essen-Mitte, Essen, Germany) and Dr Christian Marth (Innsbruck Medical University, Austria) on he use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment.

Published in October 2023

ESMO Open podcast on phase II studies

ESMO Open Editor-in-Chief Professor Christoph Zielinski discusses with Dr Anna Berghoff the importance of phase II clinical trials to both the future of cancer research and the journal.

Published in November 2022

Anthracyclines for patients with early breast cancer - a debate

Dr Valentina Guarneri, of the istituto Oncologico Veneto, Padova, Italy, and Dr Evandro de Azambuja, of the Institut Jules Bordet and L’Université Libre de Bruxelles, Brussels, Belgium, discuss the pros and cons of treating patients with early breast cancer with anthracyclines.

Published in May 2022

Current highlights in lung cancer in 2021

There continues to be significant advances made in the field of lung cancer improving survival outcomes for patients. In this podcast, Dr Jonathan Lim (a member of the ESMO Young Oncologists Committee) discusses with Prof Ben Solomon (professor in thoracic medical oncology) for his highlights on lung cancer so far in 2021.

Published in July 2021

Application of the ESMO-MCBS (V.1.1) to the field of early breast cancer therapies

The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated value scale for solid tumour anticancer treatments. Form 1 of the ESMO-MCBS, used to grade therapies with curative intent including adjuvant therapies, has only been evaluated for a limited number of studies. This is the first large-scale field testing in early breast cancer to assess the applicability of the scale to this data set and the reasonableness of derived scores and to identify any shortcomings to be addressed in future modifications of the scale.Read the full article

Published in December 2020

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.